LB Pharmaceuticals Inc Common Stock
LBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | |
|---|---|---|---|
| Revenue | $0 | $0 | $0 |
| % Growth | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 |
| % Margin | – | – | – |
| R&D Expenses | $51 | $8 | $1 |
| G&A Expenses | $14 | $4 | $1 |
| SG&A Expenses | $14 | $4 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 |
| Operating Expenses | $65 | $11 | $3 |
| Operating Income | -$65 | -$11 | -$3 |
| % Margin | – | – | – |
| Other Income/Exp. Net | $2 | $5 | -$12 |
| Pre-Tax Income | -$63 | -$6 | -$14 |
| Tax Expense | $0 | $0 | $0 |
| Net Income | -$63 | -$6 | -$14 |
| % Margin | – | – | – |
| EPS | -17.83 | -1.77 | -4.05 |
| % Growth | -907.3% | 56.3% | – |
| EPS Diluted | -17.83 | -1.77 | -4.05 |
| Weighted Avg Shares Out | 4 | 4 | 4 |
| Weighted Avg Shares Out Dil | 4 | 4 | 4 |
| Supplemental Information | – | – | – |
| Interest Income | $2 | $1 | $0 |
| Interest Expense | $0 | $5 | $2 |
| Depreciation & Amortization | $0 | $0 | $0 |
| EBITDA | -$63 | -$1 | -$12 |
| % Margin | – | – | – |